CME/CE

Drs. Neeraj Agarwal and Rana McKay discuss treatment intensification strategies in metastatic castration-sensitive prostate cancer (mCSPC), with a focus on combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) and chemotherapy. They review key clinical trial data supporting doublet and triplet regimens that improve overall survival and other clinically meaningful outcomes. The faculty examine how disease burden, metastatic pattern, genomic features, comorbidities, and patient fitness inform selection of doublet versus triplet therapy. They also highlight multidisciplinary approaches to managing treatment-related adverse events and preserving quality of life in patients receiving intensified treatment.

Generalized pustular psoriasis (GPP) can look familiar but missing it can have serious consequences. Uncover how IL-36 signaling and immune dysregulation shape disease presentation, progression, and treatment response. You’ll learn to distinguish GPP from other neutrophilic dermatoses using clinical clues, biomarkers, and diagnostic tools. Explore how emerging targeted therapies are changing what’s possible for patients who previously had limited options. Real-world strategies will help you build comprehensive, long-term management plans that go beyond symptom control. If you’ve ever second-guessed a pustular case, this activity will sharpen your clinical instincts.

Iron deficiency and iron-deficiency anemia are related but distinct clinical entities, with iron deficiency often preceding or occurring independently of anemia. In chronic kidney disease (CKD), inflammation-driven iron sequestration and impaired iron availability frequently develop before hemoglobin declines, making hemoglobin-only screening insufficient. Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD highlight the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD, along with the need for proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selection of iron replacement strategies to improve long-term patient outcomes.

On-demand webcast on the latest advances in managing inflammatory bowel disease (IBD) and expert-informed strategies for providing guideline-concordant care to patients with IBD.

Learn how to optimize guideline-concordant care for patients with type 2 diabetes with this on-demand webcast—featuring the latest data on weekly insulin therapies and expert-informed strategies to support the future integration of these emerging agents in your practice.

Part of the educational program Bridging Specialties®: Timely Diagnosis and Treatment for Refractory Chronic Cough, this activity explores emerging scientific insights and therapeutic advances shaping the management of refractory chronic cough (RCC). Despite appropriate evaluation and treatment of common etiologies, many patients continue to experience persistent cough consistent with cough hypersensitivity syndrome. Advances in understanding ATP–P2X3 signaling and neural mechanisms have reshaped the conceptual framework for RCC and informed the development of emerging therapies. This activity reviews the neurobiology of cough hypersensitivity, current management gaps, and the evolving therapeutic landscape. Clinicians will gain insight into mechanism-based care strategies and patient-centered counseling considerations in RCC management.

This Podcast Plus discussion examines how to distinguish tardive dyskinesia (TD) from other movement disorders using clinical features, medication timing, and response patterns. Key characteristics of TD, including irregular orofacial movements, are compared with drug-induced parkinsonism and akathisia. The discussion highlights the delayed onset of TD following dopamine receptor-blocking agents and compares timing across movement syndromes. It also emphasizes why TD should not be grouped with other extrapyramidal symptoms, as it may be missed, masked, or coexist with other conditions, affecting treatment decisions.

Chronic kidney disease (CKD) and high blood pressure (BP) are closely linked and, when not managed appropriately, can lead to serious outcomes such as myocardial infarction, stroke, heart failure, and progression to kidney failure. Pathological excess of aldosterone induces hypertension by forcing the kidneys to excessively retain sodium and water, increasing blood volume, and lowering potassium. Mineralocorticoid receptor antagonists (MRAs), which target the renin-angiotensin-aldosterone system (RAAS), do not fully inhibit the deleterious effects of aldosterone and may increase serum aldosterone concentrations. Highly selective aldosterone synthase inhibitors (ASIs) have emerged as potential alternatives to MRAs; ASIs decrease aldosterone synthesis, providing another strategy to inhibit aldosterone effects without affecting cortisol production.

Want to dive deeper into the discussion? Check out Audience Q&A From the Live Symposium in the Related Content section for additional expert insights and practical perspectives on CKD, hypertension, and emerging aldosterone-targeted therapies.

In this case-based discussion, Drs. Dolinger and Rubin examine the diagnostic approach to patients presenting with signs and symptoms suggestive of inflammatory bowel disease (IBD). The conversation explores key steps in the initial evaluation, appropriate laboratory testing, the role of colonoscopy versus additional noninvasive work-up, and how imaging modalities such as intestinal ultrasound contribute to disease characterization. The faculty also address methods to assess disease severity and activity, incorporating clinical indices, endoscopic findings, and risk stratification.

Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.